HepQuant Results Presented while Attending Digestive Disease Week® (DDW) 2022
SAN DIEGO (May 24, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced preliminary data from the SHUNT-V Pivotal study in oral and poster presentations at Digestive Disease Week® (DDW) 2022 in San Diego. DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
In addition, HepQuant presented data on measuring Hepatic Impairment in relation to six classes of drugs.
Abstract #1: “The HepQuant SHUNT Disease Severity Index (HepQuant DSI™) Can Aid the Decision to Avoid Endoscopic Screening or Surveillance for Varices Needing Treatment.” Presenting Author: Dr. Mitch Shiffman, Liver Institute of Virginia, Richmond, VA.
Description: The HepQuant DSI=18.3 showed strong performance in capturing large esophageal varices needing treatment and screening out subjects who didn’t (Sensitivity=97%, FNR=3%, NPV=99%) when compared with related transient elastography cutoffs applied to those in the SHUNT-V study who had transient elastography data (Sensitivity= 83%, FNR=17%, 98%).
Abstract #2: “The HepQuant’s Disease Severity Index (HepQuant DSI™) Outperforms Child-Pugh (CP) Classification in Quantifying Hepatic Impairment for Prediction of Drug Pharmacokinetics (PK) in Chronic Liver Disease.” Presenting Author: Dr. Steve Helmke, HepQuant, LLC.
Description: HepQuant DSI strongly correlated with drug pharmacokinetics in six different classes of drug showing potential utility in measuring Hepatic Impairment.
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and virtual meeting from May 21-24, 2022. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
Headquartered in Denver, Colorado, HepQuant, LLC, is a privately-held diagnostics company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA guidelines for investigational device exemptions (IDEs). For additional information, visit www.hepquant.com.
For further inquiries: Bradley C. Everson | Chief Business Development Officer
Ph: (303) 923-2150 | [email protected]
Download HepQuant-DDW Press Release